Skip to main content

Table 1 Features of breast tumours according to breast cancer patient's age (years) at diagnosis

From: Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families

 

BRCA1 tumours

BRCA2 tumours

Non-BRCA1/2 tumours

 

Age <50

Age ≥ 50

P < 0.05a

Age <50

Age ≥ 50

P < 0.05a

Age <50

Age ≥ 50

P < 0.05a

Histology

               

   Ductal cancer

24

(70.6)

13

(76.5)

 

19

(54.3)

18

(75.0)

 

34

(58.6)

68

(72.3)

 

   Lobular cancer

5

(14.7)

3

(17.6)

 

12

(34.3)

5

(20.8)

 

15

(25.9)

15

(16.0)

 

   Medullary cancer

5

(14.7)

        

2

(3.4)

1

(1.1)

 

   Other cancers

  

1

(5.9)

 

4

(11.4)

1

(4.2)

 

7

(12.1)

10

(10.6)

 

Grade

               

   I

1

(3.1)

2

(11.8)

 

7

(23.3)

5

(22.7)

 

13

(25.0)

33

(36.7)

 

   II

4

(12.5)

7

(41.2)

 

16

(53.3)

10

(45.5)

 

30

(57.7)

36

(40.0)

 

   III

27

(84.4)

8

(47.1)

0.009

7

(23.3)

7

(31.8)

 

9

(17.3)

21

(23.3)

 

   I to II

5

(16.6)

9

(53.0)

 

13

(76.7)

15

(68.2)

 

43

(82.7)

69

(76.7)

 

Immunohistochemistry

               

   ER-

25

(83.3)

3

(25.0)

0.001

7

(20.6)

10

(52.6)

0.017

17

(29.3)

23

(25.6)

 

   ER+

5

(16.7)

9

(75.0)

 

27

(79.4)

9

(47.4)

 

41

(70.7)

67

(74.7)

 

   PR-

28

(90.3)

9

(69.2)

 

12

(35.3)

16

(80.0)

0.001

18

(31.0)

49

(54.4)

 

   PR+

3

(9.7)

4

(30.8)

 

22

(64.7)

4

(20.0)

 

40

(69.0)

41

(45.6)

 

   p53-

15

(50.0)

12

(92.3)

0.014

27

(81.8)

15

(83.3)

 

43

(74.1)

75

(81.5)

 

   p53+

15

(50.0)

1

(7.7)

 

6

(18.2)

3

(16.7)

 

15

(25.9)

17

(18.5)

 

   ERBB2-

23

(76.7)

12

(92.3)

 

29

(83.3)

16

(84.2)

 

45

(81.8)

64

(83.1)

 

   ERBB2+

7

(23.3)

1

(7.7)

 

5

(14.7)

3

(15.8)

 

10

(18.2)

13

(16.9)

 
  1. Values are no. (frequency %). aComparison by age group. There were no significant differences according to patients' age in the non-BRCA1/2 tumours (rightmost column). ER, oestrogen receptor; ERBB2, ERBB2 oncoprotein; PR, progesterone receptor.